IBRX - ImmunityBio, Inc.
10
-0.440 -4.400%
Share volume: 25,946,895
Last Updated: 03-03-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.31%
PREVIOUS CLOSE
CHG
CHG%
$10.44
-0.44
-0.04%
Fundamental analysis
53%
Profitability
43%
Dept financing
43%
Liquidity
75%
Performance
60%
Performance
5 Days
2.25%
1 Month
70.07%
3 Months
334.78%
6 Months
318.41%
1 Year
231.13%
2 Year
97.24%
Key data
Stock price
$10.00
DAY RANGE
$9.80 - $10.58
52 WEEK RANGE
$1.83 - $12.43
52 WEEK CHANGE
$226.80
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-11-2025
Company detail
CEO: Richard Adcock
Region: US
Website: immunitybio.com
Employees: 590
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Region: US
Website: immunitybio.com
Employees: 590
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers.
Recent news